Skip to main content
. Author manuscript; available in PMC: 2012 Jan 21.
Published in final edited form as: ChemMedChem. 2009 Oct;4(10):1615–1629. doi: 10.1002/cmdc.200900226

Figure 5.

Figure 5

Effects of A) compound 1 and B) compound 19 administered by intraperitoneal injection on tactile allodynia in a paclitaxel-induced neuropathic pain model in rats (n =5–6 per group). C) Compound 19 dose-dependently attenuated tactile allodynia in this model, as evidenced by an increase in the percent MPE withdrawal threshold area under the curve (AUC); P <0.05 between the vehicle (V) and compound 19 at 15 mg kg−1 (ANOVA followed by Tukey–Kramer test for multiple group comparison). Compound 1 did not affect the paw withdrawal threshold. The effects of compound 1, a CB2 ligand,[103] at 1, 3, and 5 mg kg−1 were not significantly different from the effects induced by the vehicle.